Kuo‐Chih Tseng

National Yang Ming Chiao Tung University — Taiwan

Medicine · Health Sciences

22h-index2.0kcitations151works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(94), Liver Disease Diagnosis and Treatment(81), Hepatitis B Virus Studies(55), Liver Disease and Transplantation(22), Systemic Lupus Erythematosus Research(12)

Publications151 total

Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
European Journal of Cancer·2025
Prediction Model for Risk of Hepatocellular Carcinoma After Hepatitis C Viral Eradication
Journal of Hepatocellular Carcinoma·2025Open Access
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan
The Kaohsiung Journal of Medical Sciences·2025Open Access
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)
Journal of the Formosan Medical Association·2025Open Access
A Retrospective Study on Biliary Cooling During Thermal Ablation of Central Liver Tumors in Taiwan
Cancers·2025Open Access
The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders
Liver International·2025· 2 cited
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real‐World Experience From the Nationwide Taiwan Hepatitis C Virus Registry
The Kaohsiung Journal of Medical Sciences·2025Open Access
WED-272 Real-world efficacy and safety of universal 8-week Glecaprevir/ Pibrentasvir in CHC patients with early CKD or Pre-ESRD: insights from a nationwide HCV registry in Taiwan
Journal of Hepatology·2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
Journal of the Formosan Medical Association·2025· 3 citedOpen Access
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
Clinical and Molecular Hepatology·2025· 6 citedOpen Access
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
˜The œLancet. Gastroenterology & hepatology·2025· 18 cited
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C
Journal of the Formosan Medical Association·2025· 2 citedOpen Access
Incidence of HBV Reactivation in Psoriasis Patients Undergoing Cytokine Inhibitor Therapy
2024Open Access
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
Journal of the Formosan Medical Association·2024· 6 citedOpen Access
Phase Ib/IIa randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB
Journal of Hepatology·2024· 30 cited
Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan
Digestive Diseases and Sciences·2024· 3 cited
THU-365 Real-world effectiveness and safety of 8-week glecaprevir/ pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry
Journal of Hepatology·2024
OS-121 Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis
Journal of Hepatology·2024· 3 cited
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan
Infectious Diseases and Therapy·2024· 2 citedOpen Access
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
Clinical and Molecular Hepatology·2024· 13 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Cheng‐Yuan Peng(19), Jia‐Horng Kao(18), Chih‐Wei Tseng(18), Gin‐Ho Lo(17), Chun‐Jen Liu(16), Wei‐Wen Su(15), Yu‐Hsi Hsieh(14), Tsai‐Yuan Hsieh(13), Chi-Yi Chen(13), Pin‐Nan Cheng(13), Wan‐Long Chuang(12), Sheng‐Shun Yang(12), Tsung‐Hsing Hung(12), Yi‐Hsiang Huang(11), Ming‐Jong Bair(11), Pei‐Lun Lee(11), Chen‐Hua Liu(11), Ming‐Lung Yu(11), Han‐Chieh Lin(10), Jee‐Fu Huang(10)